EA201400623A1 - Новые 2h-индазолы в качестве антагонистов рецептора ep - Google Patents

Новые 2h-индазолы в качестве антагонистов рецептора ep

Info

Publication number
EA201400623A1
EA201400623A1 EA201400623A EA201400623A EA201400623A1 EA 201400623 A1 EA201400623 A1 EA 201400623A1 EA 201400623 A EA201400623 A EA 201400623A EA 201400623 A EA201400623 A EA 201400623A EA 201400623 A1 EA201400623 A1 EA 201400623A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new
indasols
epceptor
antagonists
indazoles
Prior art date
Application number
EA201400623A
Other languages
English (en)
Russian (ru)
Inventor
Нико Бройер
Анне Менгель
Ульрике Рён
Андреа Ротгери
Бернд Бухманн
Бернхард Линденталь
Антониус Тер-Лак
Original Assignee
Байер Интеллектчуал Проперти Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201400623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Интеллектчуал Проперти Гмбх filed Critical Байер Интеллектчуал Проперти Гмбх
Publication of EA201400623A1 publication Critical patent/EA201400623A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
EA201400623A 2011-11-28 2012-11-26 Новые 2h-индазолы в качестве антагонистов рецептора ep EA201400623A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011087170 2011-11-28
DE102012206715 2012-04-24
PCT/EP2012/073556 WO2013079425A1 (en) 2011-11-28 2012-11-26 Novel 2h-indazoles as ep2 receptor antagonists

Publications (1)

Publication Number Publication Date
EA201400623A1 true EA201400623A1 (ru) 2014-11-28

Family

ID=47278803

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400623A EA201400623A1 (ru) 2011-11-28 2012-11-26 Новые 2h-индазолы в качестве антагонистов рецептора ep

Country Status (24)

Country Link
US (1) US9062041B2 (OSRAM)
EP (1) EP2785707B1 (OSRAM)
JP (1) JP6192654B2 (OSRAM)
KR (1) KR20140103984A (OSRAM)
CN (1) CN104144922B (OSRAM)
AR (1) AR089011A1 (OSRAM)
AU (1) AU2012344015A1 (OSRAM)
BR (1) BR112014012459A2 (OSRAM)
CA (1) CA2856769A1 (OSRAM)
CL (1) CL2014001392A1 (OSRAM)
CO (1) CO6970595A2 (OSRAM)
CR (1) CR20140257A (OSRAM)
DO (1) DOP2014000114A (OSRAM)
EA (1) EA201400623A1 (OSRAM)
EC (1) ECSP14002542A (OSRAM)
ES (1) ES2665510T3 (OSRAM)
IL (1) IL232503A (OSRAM)
IN (1) IN2014CN03854A (OSRAM)
MX (1) MX2014006433A (OSRAM)
PE (1) PE20141579A1 (OSRAM)
PH (1) PH12014501195A1 (OSRAM)
SG (1) SG11201402269RA (OSRAM)
TW (1) TW201326154A (OSRAM)
WO (1) WO2013079425A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087814A1 (es) 2011-09-16 2014-04-16 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
MA38606A1 (fr) * 2013-05-23 2017-03-31 Bayer Pharma AG Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande
WO2014187793A1 (de) * 2013-05-23 2014-11-27 Bayer Pharma Aktiengesellschaft Verwendung einer pharmazeutischen zusammensetzung zur notfallkontrazeption
BR112016028255A2 (pt) 2014-06-06 2017-08-22 Flexus Biosciences Inc agentes imunorreguladores
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
BR112017008809A2 (pt) 2014-11-05 2017-12-19 Flexus Biosciences Inc agentes imunorreguladores
TW202039479A (zh) 2018-11-08 2020-11-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
TW202241846A (zh) * 2020-12-24 2022-11-01 日商小野藥品工業股份有限公司 具有ｅｐ拮抗活性之化合物的鹽、溶劑合物及結晶

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1152863C (zh) 1996-07-18 2004-06-09 麦克弗罗斯特(加拿大)公司 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
US7491748B2 (en) 2001-08-09 2009-02-17 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003030911A1 (en) 2001-10-08 2003-04-17 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
EP1439837B1 (en) 2001-10-23 2008-04-09 Laboratoires Serono SA Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
US20050059742A1 (en) 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
US7335680B2 (en) 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
JP2005521668A (ja) 2002-01-31 2005-07-21 ファイザー・プロダクツ・インク （３−｛［４−ｔｅｒｔ−ブチル−ベンジル）−（ピリジン−３−スルホニル）−アミノ］−メチル｝−フェノキシ）−酢酸の代謝物
CN1653046A (zh) 2002-03-05 2005-08-10 小野药品工业株式会社 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物
EP1563845A4 (en) 2002-10-10 2008-02-20 Univ Kyoto REMEDIES FOR ALLERGIC DISEASES
US7989451B2 (en) 2005-03-31 2011-08-02 Auckland Uniservices Limited Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
DK1816121T3 (da) 2005-11-21 2008-06-16 Bayer Schering Pharma Ag 9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
CA2641884A1 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1884906A1 (de) 2006-07-31 2008-02-06 Siemens Building Technologies Fire & Security Products GmbH & Co. oHG Levelsynchronisation bei Funk-Kommunikationsnetzwerken
EP1903037A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP1903038A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
EP2091329A4 (en) 2006-12-05 2011-02-23 Univ Nat Chiao Tung Indazole CONNECTIONS
CA2686517A1 (en) 2007-05-10 2008-11-20 Pfizer Limited Azetidine derivatives and their use as prostaglandin e2 antagonists
EP2002834A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2003119A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Substituierte Acetamide als Modulatoren des EP2-Rezeptors
EP2014663A1 (de) 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2014662A1 (de) 2007-07-12 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2222665A1 (en) * 2007-11-15 2010-09-01 Pfizer Limited Azetidines as ep2 antagonists
BRPI0912778B1 (pt) * 2008-05-14 2019-04-30 Astellas Pharma Inc. Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética
WO2010008777A2 (en) 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Fused azabicyclic pyridines
EP2364296A1 (en) 2008-11-10 2011-09-14 Pfizer Limited Pyrrolidines
WO2010080357A1 (en) * 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
TW201107315A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
DE102009049662A1 (de) * 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑

Also Published As

Publication number Publication date
ES2665510T3 (es) 2018-04-26
JP2014533713A (ja) 2014-12-15
CL2014001392A1 (es) 2014-10-03
IL232503A0 (en) 2014-07-01
US20140336172A1 (en) 2014-11-13
CR20140257A (es) 2014-07-15
AR089011A1 (es) 2014-07-23
TW201326154A (zh) 2013-07-01
IL232503A (en) 2015-08-31
WO2013079425A1 (en) 2013-06-06
ECSP14002542A (es) 2015-12-31
CN104144922B (zh) 2016-08-31
PH12014501195A1 (en) 2014-09-01
JP6192654B2 (ja) 2017-09-06
IN2014CN03854A (OSRAM) 2015-09-04
MX2014006433A (es) 2014-07-11
HK1203938A1 (en) 2015-11-06
AU2012344015A1 (en) 2014-05-29
NZ624722A (en) 2016-08-26
EP2785707B1 (en) 2018-01-24
CA2856769A1 (en) 2013-06-06
EP2785707A1 (en) 2014-10-08
BR112014012459A2 (pt) 2017-06-06
SG11201402269RA (en) 2014-09-26
PE20141579A1 (es) 2014-11-15
KR20140103984A (ko) 2014-08-27
CO6970595A2 (es) 2014-06-13
DOP2014000114A (es) 2014-07-15
US9062041B2 (en) 2015-06-23
CN104144922A (zh) 2014-11-12

Similar Documents

Publication Publication Date Title
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201390576A1 (ru) Противовирусные соединения
EA201490037A1 (ru) Антагонисты trpv4
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201790963A1 (ru) Противовирусные соединения
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201391106A1 (ru) Новые гетероциклические производные
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
EA201300388A1 (ru) Соединения замещенного бензамида
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201590562A1 (ru) Бензамиды
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201201296A1 (ru) Способы лечения диабетических язв стопы
EA201400444A1 (ru) Производные 2-оксопиперидинила
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
CU20140058A7 (es) Nuevos 2h-indizoles como antagonistas del receptor ep-2